The controversy surrounding Covid-19’s origin continues to heat up, as the National Institutes of Health’s recent removal of genetic data about the novel coronavirus virus from the NIH archive was brought into the spotlight.
AbbVie and Harvard University entered into a $30 million collaborative research alliance to develop therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.
Two European patients were confirmed to have been re-infected with the coronavirus, raising concerns about people’s immunity to the virus as the world struggles to tame the pandemic.
This panel discussion will feature the top minds in infectious diseases, virology and vaccinology, who will give participants a breakdown of the top vaccine candidates and the latest information on clinical trials.
The U.S. Food and Drug Administration issued guidelines for where the regulatory agency will set the bar for approval of a vaccine for COVID-19.
Danaher Corp. said it would buy medical diagnostics company Cepheid in a deal valued at $4 billion that will strengthen its presence in molecular diagnostics.